MiMedx sees Fy24 adjusted EBITDA as percent of sales above 20%

MiMedx stated: “The Company’s goal is to deliver net sales percentage growth in the low double-digits annually. In 2024, the Company expects to see continued growth in both the Wound and Surgical end markets, despite more difficult prior year growth comparisons. In particular, the Company continues to anticipate solid growth in the private office setting driven by the recent launch of EPIEFFECT and ongoing changes in purchasing behaviors related to Medicare reimbursement. Additionally, the Company expects to continue to drive growth across a variety of Surgical use cases as the body of evidence for utilization of its Surgical products, such as AMNIOEFFECT, continues to grow. For the full year 2024, the Company expects its Adjusted EBITDA as a percent of net sales to be above 20%.”